Charles Samuel, Wiseman Scott, Savadelis Molly D, Nichols Eric, Young Lisa
Elanco Animal Health, 2500 Innovation Way, Greenfield, IN, 46140, USA.
Elanco Animal Health, Bartley Way, Hook, Hants, RG27 9XA, UK.
Parasit Vectors. 2025 Jul 25;18(1):297. doi: 10.1186/s13071-025-06932-7.
Gastrointestinal nematodes such as hookworms (Ancylostoma caninum) and roundworms (Toxocara canis) commonly infect dogs and are zoonotic parasites capable of producing clinical disease in humans. This field study was conducted to confirm the clinical effectiveness and field safety of a novel, chewable tablet (Credelio Quattro) containing lotilaner, moxidectin, praziquantel, and pyrantel (as pamoate salt) as compared with a control product containing sarolaner, moxidectin, and pyrantel (as pamoate salt) for the treatment of naturally occurring gastrointestinal nematode infections in dogs.
In this multicenter field study, 158 dogs were enrolled with an evaluable safety population of 155 dogs and an evaluable effectiveness population of 109 dogs. Dogs were randomized in a 2:1 ratio to receive either the investigational veterinary product (IVP) Credelio Quattro containing lotilaner, moxidectin, praziquantel, and pyrantel or the control product (CP) containing sarolaner, moxidectin, and pyrantel. On Day 0, after confirmation of infection, enrolled dogs were randomized, dispensed, and administered IVP or CP. Enrolled dogs returned to the study site on Day 10 (± 2 d) to quantify the concentration of nematode eggs post-treatment.
Post-treatment fecal egg counts performed on Day 10 demonstrated a 99.9% reduction in A. caninum eggs per gram in both IVP-treated dogs and CP-treated dogs. In addition, a 98.7% and 96.6% reduction in T. canis fecal egg counts were observed in IVP- and CP-treated dogs, respectively. Adverse events were reported in both treatment groups. The most common adverse events reported in the IVP group included gastrointestinal signs, such as diarrhea and emesis, as well as lethargy.
This field study demonstrated that Credelio Quattro, a novel oral combination chewable tablet administered at the labeled dose ranges of 20-40 mg/kg lotilaner, 0.02-0.04 mg/kg moxidectin, 5-10 mg/kg praziquantel, and 5-10 mg/kg pyrantel (as pamoate salt), is safe and effective for the treatment and control of naturally occurring A. caninum and T. canis infections in dogs.
胃肠道线虫，如钩虫（犬钩口线虫）和蛔虫（犬弓首蛔虫），通常感染犬类，并且是能够在人类中引发临床疾病的人畜共患寄生虫。开展这项现场研究是为了确认一种新型咀嚼片（Credelio Quattro）的临床有效性和现场安全性，该咀嚼片含有洛替拉纳、莫昔克丁、吡喹酮和噻嘧啶（作为双羟萘酸盐），并将其与一种含有沙罗拉纳、莫昔克丁和噻嘧啶（作为双羟萘酸盐）的对照产品相比较，用于治疗犬类自然发生的胃肠道线虫感染。
在这项多中心现场研究中，共纳入158只犬，其中可评估安全性的犬有155只，可评估有效性的犬有109只。犬按2:1的比例随机分组，分别接受含有洛替拉纳、莫昔克丁、吡喹酮和噻嘧啶的试验用兽用产品（IVP，即Credelio Quattro）或含有沙罗拉纳、莫昔克丁和噻嘧啶的对照产品（CP）。在第0天，确认感染后，将纳入的犬随机分组、分发并给予IVP或CP。纳入的犬在第10天（±2天）返回研究地点，以量化治疗后线虫卵的浓度。
在第10天进行的治疗后粪便虫卵计数显示，IVP治疗组和CP治疗组每克粪便中犬钩口线虫卵的数量均减少了99.9%。此外，IVP治疗组和CP治疗组犬弓首蛔虫粪便虫卵计数分别减少了98.7%和96.6%。两个治疗组均报告了不良事件。IVP组报告的最常见不良事件包括胃肠道症状，如腹泻和呕吐，以及嗜睡。
这项现场研究表明，Credelio Quattro是一种新型口服复方咀嚼片，按20 - 40mg/kg洛替拉纳、0.02 - 0.04mg/kg莫昔克丁、5 - 10mg/kg吡喹酮和5 - 10mg/kg噻嘧啶（作为双羟萘酸盐）的标记剂量范围给药，对于治疗和控制犬类自然发生的犬钩口线虫和犬弓首蛔虫感染是安全有效的。
